In the ongoing battle against eczema, a skin condition that plagues millions with dry, itchy, and inflamed skin, a ray of hope shines from the laboratories of New York Medical. A recent study spearheaded by postdoctoral fellow Anish R. Maskey, Ph.D., has brought to light the promising effects of berberine, a natural compound, in the fight against eczema exacerbated by the bacterium Staphylococcus aureus.
Eczema sufferers are all too familiar with the temporary relief that topical antibiotics provide, only to be overshadowed by the looming threat of antibiotic resistance. Moreover, the use of steroids carries the risk of topical steroid withdrawal (TSW) syndrome. However, Maskey’s research, presented at ASM Microbe, offers a glimpse into a future where eczema can be managed more effectively without these adverse effects.
The study delved into the altered skin microbiome associated with eczema, highlighting the higher colonisation by S. aureus. Through comprehensive analyses, including whole genome sequencing of isolated S. aureus strains from eczema patients, the team uncovered resistance and toxin-encoding genes that emphasise the need for alternative treatments.
Berberine emerged as a beacon of hope in this study, showcasing its ability to inhibit S. aureus colonisation and alleviate eczema symptoms through its anti-inflammatory properties and suppression of mast cell degranulation—a pivotal process in eczema’s progression.
The mechanistic insights gained from this research revealed berberine’s capacity to suppress genes linked to inflammatory pathways. Computational modelling further pinpointed key targets in the PI3K/AKT pathways, underscoring berberine’s potential as a therapeutic agent.
“Berberine may be a valuable natural product for the treatment of multi-drug resistant S. aureus-exacerbated eczema due to its antibacterial and anti-inflammatory [effects] and inhibition of mast cell degranulation,” stated Maskey.
This groundbreaking research was made possible through funding from The Lie and Artati Family Fund and the Study of Integrative Medicine Fund, marking a significant stride towards more effective management of eczema.
